Loading...
•
Jun 30, 2022
Corbus Pharmaceuticals Q2 2022 Earnings Report
Corbus Pharmaceuticals reported financial results for the second quarter of 2022 and provided a corporate update.
Key Takeaways
Corbus Pharmaceuticals reported a net loss of $13.2 million for the second quarter of 2022. The company's cash and investments on hand of $74 million are expected to fund operations into the first quarter of 2024.
Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy.
IND submission for CRB-601 is on track for mid-2023.
Expanding immuno-oncology pipeline through strategic transactions remains key priority.
Cash and investments on hand of $74 million funds operations into the first quarter of 2024.
Corbus Pharmaceuticals
Corbus Pharmaceuticals
Forward Guidance
Corbus is continuing the transformation into a company with a novel and diversified immuno-oncology pipeline.